Resources
22 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 5/3/2021 (updated 4/10/2024)
Building on Part I of the stigma webinar series and its introduction of a statewide collective impact model for addressing stigma, this webinar delivered the first part of the model that also served as its conceptual framework. This webinar introduced the stages of change and showed grantees how these apply to their target populations. We also discussed how those same principles applied to grantee engagement of community stakeholders and their openness to evidence-based practices that reduce morbidity and mortality related to SUD/OUD.
Posted 4/28/2021 (updated 4/10/2024)
Many people use opioids and are at risk of overdose. Naloxone is an opioid antagonist used to counter the effects of opioid overdose. There is an increased availability of naloxone in New York City; however, many who use opioids decline no-cost naloxone even when offered. Others may have the medication but opt not to carry it and report that they would be reluctant to administer it if they were to witness an overdose.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/30/2021 (updated 4/5/2024)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 11/11/2021 (updated 4/3/2024)
In these challenging times, some of our most important problems are intractable. Examples include health inequity, hybrid workplaces, systemic racism, maternal and child health, and a trained and available workforce. In this session, presenters introduced tools to help you lead, even when solutions are beyond your control. They applied those tools to help you recruit and sustain a workforce for tomorrow.
Posted 10/27/2021 (updated 4/3/2024)
Posted 10/14/2021 (updated 4/3/2024)
Participants learned evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters discussed methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Robert Childs, MPH, JBS International
Christine Rodriguez, MPH, Vital Strategies
Posted 10/13/2021 (updated 4/3/2024)
Over the past twenty years a large number of new psychoactive substances (NPS) have entered and modified the recreational drug scene. Their intake has been associated with health-related risks, especially so for vulnerable populations such as people with severe mental illness, who might be at higher risk of suicidality or self-injurious behavior. This paper aims at providing an overview of NPS abuse and the effects on mental health and suicidality issues, by performing a literature review of the current related knowledge, thereby identifying those substances that, more than others, are linked to suicidal behaviors.